InflaRx (IFRX) Cash from Investing Activities (2016 - 2026)
InflaRx (IFRX) posted Cash from Investing Activities of $7.2 million for Q1 2026, down 21.65% sequentially from $9.2 million in Q4 2025, and down 61.3% YoY from $18.6 million in Q1 2025.
InflaRx (IFRX) Cash from Investing Activities (2016 - 2026) Analysis & Trends
InflaRx has reported Cash from Investing Activities for 11 years, with the latest figure at $7.2 million in Q1 2026.
- Quarterly Cash from Investing Activities fell 61.3% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.8 million (down 118.98% YoY) and the FY2025 annual result came in at $3.7 million, down 93.56% from the prior year.
- Cash from Investing Activities slipped to $7.2 million in Q1 2026 per IFRX's latest filing, from $9.2 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $29.7 million in Q1 2022 and troughed at -$28.2 million in Q2 2025.
- A 5-year average of $4.1 million and a median of $5.0 million in 2022 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 2447.57% in 2022, down 1281.91% in 2022.
- Over 5 years, Cash from Investing Activities stood at $1.8 million in 2022, then soared by 64.91% to $3.0 million in 2023, then plunged by 31.24% to $2.1 million in 2024, then soared by 338.76% to $9.2 million in 2025, then decreased by 21.65% to $7.2 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $7.2 million, $9.2 million, and $3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | 14.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.19 Mn |
| Mar 31, 2026 | 7.19 Mn |
| Dec 31, 2025 | 9.17 Mn |
| Dec 31, 2025 | 9.17 Mn |
| Sep 30, 2025 | 3.04 Mn |
| Sep 30, 2025 | 3.04 Mn |
| Jun 30, 2025 | -28.19 Mn |
| Jun 30, 2025 | -28.19 Mn |
| Mar 31, 2025 | 18.57 Mn |
| Mar 31, 2025 | 18.57 Mn |
| Dec 31, 2024 | 2.09 Mn |
| Dec 31, 2024 | 2.09 Mn |
| Sep 30, 2024 | 19.19 Mn |
| Sep 30, 2024 | 19.19 Mn |
| Jun 30, 2024 | 6.45 Mn |
| Jun 30, 2024 | 6.45 Mn |
| Mar 31, 2024 | 29.27 Mn |
| Mar 31, 2024 | 29.27 Mn |
| Dec 31, 2023 | 3.04 Mn |
| Dec 31, 2023 | 3.04 Mn |